Zentalis Pharmaceuticals, Inc. (ZNTL)

♥ 690 Thanks from members

Zentalis Pharmaceuticals exhibits a mixed market sentiment; while bullish momentum persists around azenosertib's accelerated ovarian cancer approval path and strengthened cash runway from a $92.6M offering, alternative data flags lagging web traffic and short-term fundamental pressures.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →

Other Nasdaq Tickers

NASDAQ

Microchip Technology Incorporated (MCHP)

NASDAQ

Direxion Daily AAPL Bear 1X ETF (AAPD)

NASDAQ

Ascentage Pharma Group International - American Depository Shares (AAPG)

NASDAQ

Direxion Daily AAPL Bull 2X ETF (AAPU)

NASDAQ

Alpha Blue Capital US Small-Mid Cap Dynamic ETF (ABCS)

NASDAQ

AbCellera Biologics Inc. - Common Shares (ABCL)

Entity & Market Metadata

Sector: Healthcare Industry: Biotechnology Founder: Camilla Erickson Founder: David Wroblewski Leadership: Kamal Fadili (CEO) Holder: Baker Bros. Advisors Holder: Fidelity Management Holder: Vanguard Group Camonsertib ZN-c3 Oncology Therapeutics #Zentalis Pharmaceuticals #ZNTL #biotech stock #cancer therapeutics #NASDAQ ZNTL